首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Prior Caspofungin Exposure in Patients with Hematological Malignancies Is a Risk Factor for Subsequent Fungemia Due to Decreased Susceptibility in Candida spp.: a Case-Control Study in Paris France
【2h】

Prior Caspofungin Exposure in Patients with Hematological Malignancies Is a Risk Factor for Subsequent Fungemia Due to Decreased Susceptibility in Candida spp.: a Case-Control Study in Paris France

机译:血液恶性肿瘤患者先前接受卡泊芬净的暴露是由于念珠菌易感性降低而导致随后的真菌病的危险因素:法国巴黎的病例对照研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Infections due to caspofungin-resistant Candida isolates in patients exposed to caspofungin therapy are increasing. We report here a nested case-control study which aimed at identifying factors associated with bloodstream infections caused by Candida spp. having reduced susceptibility to caspofungin (CRSC) in adults suffering from hematological malignancies. In univariate and multivariate analyses, infections with CRSC were associated with caspofungin exposure in the previous 30 days (odds ratio [OR] = 5.25; 95% confidence interval [95% CI], 1.68–16.35) and with an age of ≤65 years (OR = 3.27; 95% CI, 1.26–8.50).
机译:接受卡泊芬净治疗的患者中因卡泊芬净耐药的念珠菌分离株引起的感染正在增加。我们在这里报告了一项嵌套的病例对照研究,旨在确定与念珠菌引起的血液感染相关的因素。在患有血液系统恶性肿瘤的成年人中降低了对卡泊芬净(CRSC)的敏感性。在单因素和多因素分析中,CRSC感染与前30天内卡泊芬净暴露相关(几率[OR] = 5.25; 95%置信区间[95%CI],1.68–16.35),年龄≤65岁(OR = 3.27; 95%CI,1.26-8.50)。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号